Randomized Trialhigh evidence
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
The New England journal of medicine·July 29, 2026·PMID 42525925
Why it mattersAdherence to daily oral HIV therapy remains a challenge, and long-acting options can reduce pill burden and dosing frequency. This trial provides high-level evidence that a once-weekly oral regimen maintains virologic suppression comparably to a standard daily regimen, potentially offering a new treatment strategy for patients who prefer less frequent dosing.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled